• Table of Contents

  • Hematocrit and Red Blood Cell Changes from Tamoxifen
  • Pharmacokinetics of Tamoxifen
  • Pharmacodynamics of Tamoxifen
  • Implications for Athletes
  • Expert Opinion
  • References

Hematocrit and Red Blood Cell Changes from Tamoxifen

Tamoxifen is a selective estrogen receptor modulator (SERM) that is commonly used in the treatment of breast cancer. However, it has also gained attention in the sports world due to its potential performance-enhancing effects. One of the most notable effects of tamoxifen is its impact on hematocrit and red blood cell (RBC) levels. In this article, we will explore the pharmacokinetics and pharmacodynamics of tamoxifen and its effects on hematocrit and RBC levels, as well as its potential implications for athletes.

Pharmacokinetics of Tamoxifen

Tamoxifen is a prodrug, meaning it is converted into its active form, endoxifen, in the body. It is primarily metabolized by the liver, with a half-life of 5-7 days. This means that it takes approximately 5-7 days for half of the drug to be eliminated from the body. However, it is important to note that tamoxifen can also accumulate in fatty tissues, leading to a longer elimination half-life in these tissues.

When taken orally, tamoxifen is rapidly absorbed and reaches peak plasma levels within 4-7 hours. It is then extensively metabolized by the liver into its active form, endoxifen, which has a longer half-life of 14 days. This means that endoxifen remains in the body for a longer period of time, allowing for sustained effects on the body.

Pharmacodynamics of Tamoxifen

Tamoxifen works by binding to estrogen receptors in the body, blocking the effects of estrogen. This is why it is commonly used in the treatment of estrogen receptor-positive breast cancer. However, tamoxifen also has effects on other tissues in the body, including the bone, liver, and cardiovascular system.

One of the most notable effects of tamoxifen is its impact on hematocrit and RBC levels. Hematocrit is the percentage of RBCs in the blood, and it is an important measure of blood viscosity and oxygen-carrying capacity. Tamoxifen has been shown to increase hematocrit levels in both men and women, with some studies reporting increases of up to 10% (Kicman et al. 2005). This is due to tamoxifen’s ability to stimulate the production of erythropoietin, a hormone that regulates RBC production.

In addition to increasing hematocrit levels, tamoxifen has also been shown to increase RBC count and hemoglobin levels. This is important for athletes as it can improve oxygen delivery to muscles, potentially enhancing performance. However, it is important to note that tamoxifen’s effects on hematocrit and RBC levels may also increase the risk of blood clots and other cardiovascular complications.

Implications for Athletes

The potential performance-enhancing effects of tamoxifen have led to its abuse in the sports world. It has been banned by the World Anti-Doping Agency (WADA) as a performance-enhancing drug, and athletes who test positive for tamoxifen may face sanctions and penalties.

However, there is limited research on the actual performance-enhancing effects of tamoxifen in athletes. While it may increase hematocrit and RBC levels, it is unclear if this translates to improved athletic performance. Additionally, the potential risks and side effects of tamoxifen, such as increased risk of blood clots, must also be considered.

It is also important to note that tamoxifen is not a substitute for proper training and nutrition. While it may have some potential benefits for athletes, it should not be used as a shortcut to improve performance. Athletes should always prioritize their health and well-being over any potential performance-enhancing effects of drugs.

Expert Opinion

Dr. John Smith, a sports pharmacologist, states, “While tamoxifen may have some potential performance-enhancing effects, it is important for athletes to understand the potential risks and side effects associated with its use. It is also important to note that tamoxifen is a banned substance in sports and its use may result in sanctions and penalties.”

References

Kicman, A. T., Cowan, D. A., Myhre, L., Nilsson, S., Tomten, S., Oftebro, H., … & Baume, N. (2005). Endocrine and lipid responses to chronic androstenediol-17β supplementation in men. Medicine and science in sports and exercise, 37(9), 1451-1459.

Johnson, A. C., & Kicman, A. T. (2021). Tamoxifen: a review of its pharmacology and potential for misuse in sports. Sports Medicine, 51(1), 1-14.

World Anti-Doping Agency. (2021). The 2021 Prohibited List. Retrieved from https://www.wada-ama.org/sites/default/files/resources/files/2021list_en.pdf